Latest News and Press Releases

Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland Lugano, Switzerland – June 12, 2024 – Helsinn Group (“Helsinn”), a global...

Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic Lugano...

Helsinn closes financing agreement with BancaStato to support business objectives and growth New funding secured to expand the portfolio of late- and commercial-stage supportive care, oncology and...

Lugano, Switzerland, June, 12, 2023 - Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in...

Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs Lugano, Switzerland, February 3, 2023 - Helsinn Group (“Helsinn”), a fully integrated...

Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023 –...

Helsinn closes financing agreement with Oberland Capital Funding secured to expand the portfolio of late- and commercial-stage oncology and rare disease products through in-licensing or acquisitionDr...

Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer - Giorgio Calderari appointed Vice Chairman of the Board Lugano, Switzerland, January 9, 2023 - Helsinn Group...

Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist Lugano, Switzerland, January 4, 2023 - Helsinn Group (“Helsinn”), a fully integrated...

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 - Helsinn Group (“Helsinn”), a fully integrated global...